2320P Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC studyMichiel Zietse, Frederick W. Thielen, Esther R van Staveren et al.|Annals of Oncology|2025Cited by 0